Next Article in Journal
Properly Substituted Cyclic Bis-(2-bromobenzylidene) Compounds Behaved as Dual p300/CARM1 Inhibitors and Induced Apoptosis in Cancer Cells
Next Article in Special Issue
Second-Generation Pharmacological Chaperones: Beyond Inhibitors
Previous Article in Journal
7-Acetoxycoumarin Inhibits LPS-Induced Inflammatory Cytokine Synthesis by IκBα Degradation and MAPK Activation in Macrophage Cells
Previous Article in Special Issue
Self-Nanoemulsifying Drug Delivery Systems for Enhancing Solubility, Permeability, and Bioavailability of Sesamin
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 25
Issue 14
10.3390/molecules25143125
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

In Vitro Antimycobacterial Activity and Physicochemical Characterization of Diaryl Ether Triclosan Analogues as Potential InhA Reductase Inhibitors

by
Tarek S. Ibrahim
1,2,*,
Ehab S. Taher
3,
Ebtihal Samir
4,
Azizah M. Malebari
1,
Ahdab N. Khayyat
1,
Mamdouh F. A. Mohamed
5,
Riham M. Bokhtia
2,6,
Mohammed A. AlAwadh
1,
Israa A. Seliem
2,6,
Hani Z. Asfour
7,
Nabil A. Alhakamy
8,
Siva S. Panda
6,* and
Amany M. M. AL-Mahmoudy
2
1
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia
2
Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt
3
Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, Assiut 71524, Egypt
4
Physical Chemistry, Department of Analytical Chemistry, Faculty of Pharmacy, Deraya University, New Minia 61519, Egypt
5
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Sohag University, Sohag 82524, Egypt
6
Department of Chemistry & Physics, Augusta University, Augusta, GA 30912, USA
7
Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia
8
Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia
*
Authors to whom correspondence should be addressed.
Molecules 2020, 25(14), 3125; https://doi.org/10.3390/molecules25143125
Submission received: 28 January 2020 / Revised: 5 July 2020 / Accepted: 6 July 2020 / Published: 8 July 2020
(This article belongs to the Special Issue Development of Potential Drugs Based on Small Molecules)
Browse Figures
Versions Notes

Abstract

:
Two sets of diphenyl ether derivatives incorporating five-membered 1,3,4-oxadiazoles, and their open-chain aryl hydrazone analogs were synthesized in good yields. Most of the synthesized compounds showed promising in vitro antimycobacterial activity against Mycobacterium tuberculosis H37Rv. Three diphenyl ether derivatives, namely hydrazide 3, oxadiazole 4 and naphthylarylidene 8g exhibited pronounced activity with minimum inhibitory concentrations (MICs) of 0.61, 0.86 and 0.99 μg/mL, respectively compared to triclosan (10 μg/mL) and isoniazid (INH) (0.2 μg/mL). Compounds 3, 4, and 8g showed the InhA reductase enzyme inhibition with higher IC50 values (3.28–4.23 µM) in comparison to triclosan (1.10 µM). Correlation between calculated physicochemical parameters and biological activity has been discussed which justifies a strong correlation with respect to the inhibition of InhA reductase enzyme. Molecular modeling and drug-likeness studies showed good agreement with the obtained biological evaluation. The structural and experimental information concerning these three InhA inhibitors will likely contribute to the lead optimization of new antibiotics for M. tuberculosis.

Graphical Abstract

1. Introduction

Tuberculosis (TB), caused mainly by Mycobacterium tuberculosis (MTB), remains the world’s deadliest infection, having recently surpassed HIV as the leading cause of infectious disease mortality. The risk of developing tuberculosis (TB) is estimated as 16–27 times greater in people living with HIV than among those without HIV infection [1]. About 4500 people lose their lives, and close to 30,000 people fall ill each day with this preventable and curable disease [2]. The treatment plan for MTB infection is strenuous, requires long-term treatment of combination chemotherapy of two or more drugs, like pyrazinamide, isoniazid (INH), rifampicin, streptomycin and/or ethambutol (Figure 1). This combination usually accompanied by poor patient compliance, which leads to emerging of multi-drug resistant (MDR-TB) strains [3].
Although one possible long-term solution to this issue is a better vaccine, in the near future, the major reliance will be on chemotherapy requiring an urgent development of potential, non-toxic, and effective antitubercular agents against latent MTB. In the search for novel TB lead candidates, the enoyl-acyl carrier protein, InhA reductase has become a target of interest by pharmaceutical companies and academic institutions for the development of new anti-tubercular drugs. InhA is the key enzyme that catalyzes NADH-dependent reduction of 2-trans-enoyl-ACP (acyl carrier protein) to give up NAD+ and reduced enoyl thioester-ACP substrate, which in turn, aids in the synthesis of mycolic acid. Mycolic acid is a unique signature fatty acid and considered as a core constituent of the mycobacterial cell wall [4]. InhA enzyme has been identified as the key target of the most currently existing anti-TB drugs isoniazid (INH), and ethionamide. Most cases of resistance to these drugs result from mutations in the mycobacterial activating enzyme (catalase-peroxidase KatG for isoniazid and EthA for ethionamide) [5,6,7,8,9,10,11,12,13]. Also, triclosan (Figure 2), the non-ionic lipophilic anti-TB agent, has been identified as a promising reversible inhibitor of InhA. This diphenyl ether molecule doesn’t require any bioactivation and capable of directly inhibit InhA. This approach probably allows avoiding the dominant cause of the resistance to isoniazid consisting of KatG mutations. SAR studies of triclosan revealed that chlorine atoms in ring B are not significant in the activity while ring B itself is essential moiety for inhibition of InhA (Figure 2); it makes several hydrophobic contacts with adenoyl acyl carrier protein reductase enzyme. The ether oxygen bond is also crucial for the activity due to two reasons. Initially, it is necessary for maximizing the interaction of triclosan with InhA and consequently better biological activity [14]. Secondly, being of critical in the formation of the stable ternary InhA-triclosan-NAD+ complex. Replacement of this group by a sulfur atom abolishes the inhibitory activity [13,15]. Different literature studies have been carried out based on the above hypothesis. Yang and coworkers carried out several of Des-chloro-diphenyl ether derivatives such as A and B (Figure 2), in the absence of the phenolic group, to enhance pharmacokinetic and pharmacodynamic properties thereby improving the druggability of triclosan. These compounds showed good antitubercular potency against MTB strain H37Rv (Figure 2) [16].
On the other facet, oxadiazoles represent an important class of 5-membered heterocyclic systems that cover a broad range of biological activities such as antimycobacterial [17], pesticide [18], anti-inflammatory and analgesic [19], antimicrobial [20] and antitumor [21,22], In the search of more effective anti-tuberculosis, oxadiazole is one of the most versatile scaffolds against MTB strain. Interestingly, extensive chemical and structural investigations have been performed by Kini and his group through developing series of oxadiazole o/m/p-substituted diphenyl ether derivatives (C–E) which displayed inhibition against the growth of the H37Rv strain of mycobacterium (Figure 2) [9]. The hydrazide hydrazone skeleton is also a class of privileged structures with a broad range of biological activities such as antioxidant [23], anti-inflammatory [24], and antitubercular activities [25,26]. Recently, in a high throughput screening for inhibitors of M. tuberculosis H37Rv, several aryl hydrazine derivatives (F–H, Figure 2) [27] were found to possess potent activity in combination with the relatively low toxicity [27]. However, despite the promising in vitro activity of the currently existing diphenyl ethers have poor bioavailability [28] and limited aqueous solubility [28], which is likely one reason why they have limited in vivo efficacy [10].
In continuation of our previous work in parallel to the above findings and the observed relationship between lipophilicity and in vivo efficacy, especially as it pertains to antimicrobial agents [5,6,7,8,9,10,11,12], new diphenyl ether analogs have been designed as potential antitubercular inhibitors of InhA reductase enzyme. This approach developed by keeping the known essential functional groups for the activity. Modification has been made to the diphenyl ether ‘B’ ring of diphenyl ether through binding the B ring with five-membered oxadiazole moieties either substituted or non-substituted ones; this might enhance bioactivity, pharmacokinetics or pharmacodynamics properties and could be a good lead for the generation of InhA reductase inhibitors. Furthermore, the substitution of the para position of diphenyl ether ‘B’ ring with aryl hydrazine or arylidene moiety as an open-chain analog of oxadiazole may improve solubility and enhance the antimycobacterial activity. Prediction of correlation between antitubercular activity with both Clog P and IC50 of InhA inhibition has been represented. Also, the correlation of the anti-TB activity with different thermodynamic, topological parameters was also considered. Molecular modeling studies were carried out to better understand the observed activity and determine the most important structural parameters participating in binding with InhA reductase that may affect the biological activity.

2. Results and Discussion

2.1. Chemistry

The target derivatives were prepared through the conversion of the starting phenoxybenzoic acid 1 into the corresponding ester 2 using methanol and concentrated sulphuric acid under reflux conditions [28,29,30]. Hydrazinolysis of the ester 2 with hydrazine hydrate gives the hydrazide 3 (Scheme 1). Cyclocondensation of hydrazide 3 through its reaction with triethyl orthoformate under refluxing conditions led to the formation of the oxadiazole 4 (Scheme 2). The reaction of the hydrazide 3 with the appropriate aromatic carboxylic acid derivatives 5a–l in the presence of phosphorus oxychloride afforded the corresponding 5-aryl-substituted oxadiazoles 6a–l. The condensation reaction of hydrazide 3 with variant aromatic aldehydes 7a–k resulted in the formation of anticipated arylidenes 8a–k (Scheme 2). The prepared target compounds were characterized by spectral studies.

2.2. Biology

2.2.1. Anti-Tubercular Activity

Compounds 3, 4, 6a–l and 8a–k were evaluated for antitubercular activity against Mycobacterium tuberculosis H37Rv using the standard Microplate Alamar Blue Assay (MABA) protocol (Table 1) [31,32]. The MIC reported as the lowest concentration (μg/mL) of targets inhibited the growth of an organism. Triclosan and INH were used as reference standards. Among the tested compounds, the results displayed that most of them i.e., 3, 4, 6h, 6i, 6l, 8g, and 8k showed promising anti-tubercular activity (MIC, 0.61–1.69 μg/mL) in comparison to triclosan (MIC, 10 μg/mL) and INH (MIC, 0.2 μg/mL).
The structure-activity relationship acquired suggested that installing the open-chain oxadiazole moiety into the diphenyl ether caused a remarkable increase in activity as seen in compound 3 (MIC, 0.86 μg/mL). Interestingly, the cyclic and unsubstituted oxadiazole 4 (MIC, 0.61 μg/mL) showed experienced and superior activity than all the 5-substituted analogs. Noteworthy, the 5-phenyl 6a and 5-benzyloxy-phenyl 6f derivatives experienced a slight decrease in activity with MIC of 2.74, 8.23 μg/mL, respectively. It was noted, however, that replacement of the phenyl group at the oxadiazole ring with a six-membered heterocyclic system showed a slight improvement in the activity as depicted in compounds 6h and 6i (MIC, 1.40 μg/mL) while alteration of this ring into 5-membered one exhibited less activity such as 6k (MIC, 3.65 μg/mL). Expectedly, bis(diphenylether) oxadiazole 6l was the most active in this 5-substituted series (1.17 μg/mL) that may be due to the incorporation of extra phenyl ether nucleus to the backbone. The substitutions on the 5-aryl groups have a deleterious effect on biological activity especially the activating methoxy substituents in compounds 6b and 6c.
In a related vein, the arylidene group of compounds 8a–k was found comparably less active in vitro where this situation may modify in vivo, as we know arylidenes are prodrugs. By comparing these derivatives, it is clear that the introduction of the heterocyclic system into the diphenyl ether hydrazone structure either five, compound 8j (MIC, 6.35 μg/mL) or six-membered ring system, compounds 8h–i (MIC ~ 6.90 μg/mL) caused a decrease in the anti-tubercular activity. Similarly, replacement of the heterocyclic ring with substituted phenyl group i.e., compounds 8d (MIC, 7.67 μg/mL) and 8e (MIC, 2.89 μg/mL) showed weak inhibition. Surprisingly, a remarkable increase in the activity was observed for compounds 8g (0.98 μg/mL; Ar = Napthyl) and 8k (MIC, 1.69 μg/mL; Ar = thienyl). Generally, the order of activity against MTB strain H37Rv of diphenyl ether bearing arylidene core was Ar = zero > naphthyl > thienyl > p-Cl-phenyl > 3 pyridinyl ~ 4-pyridinyl > p-NO2-phenyl. All these data suggested that the diaryl ether scaffold is very important for the antitubercular activity, removal of the o-chloro group in triclosan, as well as the introduction of oxadiazole or its open-chain analog hydrazide, increased activity than the parent triclosan. In conclusion, compounds 3, 4, 6h, 6i, 6l, 8g, and 8k showed higher antitubercular activity than the reference standard triclosan. Three potential lead candidates 3 and 4 and 8g were found to be the most active in which hydrazide oxadiazole or naphthyl arylidine moieties are directly attached to an unsubstituted diphenyl ether core. Their structural features could be further investigated for their potential use as new anti-TB drugs.

2.2.2. In Vitro InhA Reductase Enzyme Inhibition

The in vitro inhibitions data of the target compounds for the InhA reductase enzyme are presented as IC50 µM values in Table 1. Among the tested compounds, the highly active hydrazide 3 and oxadiazole 4 and naphthyl arylidine 8g showed the highest inhibition of InhA reductase with IC50 of 3.43 µM and 3.28 µM and 4.23 µM, respectively, but still less than the reference triclosan (IC50, 1.10 µM). On the other hand, oxadiazole derivatives 6a–c and the corresponding arylidenes 8a–c showed deleterious activity as inhibitors for InhA reductase. The oxadiazoles 6h, 61 and arylidine 8k ether derivatives experienced good inhibition activities with IC50 of 5.08, 5.63, and 5.61, respectively. In general, most of the tested target compounds showed good inhibition for InhA reductase. Besides, other compounds show promising activity against H37Rv strain of M. tuberculosis. We believe, additional modes of mechanisms involved in the activity.
Moreover, calculated results showed a slight correlation between the molecular weight, Wiener index, and topological diameter to biological activity with R = 0.308, 0.315, 0.259, respectively. These results indicate the importance of the overall volume of a molecule on the biological activity, but it is not the only factor affecting biological activity. On the other hand, it was found that all the thermodynamic parameters (i.e., molar refractivity and Gibbs free energy and heat formation) have a negative correlation with the biological activity where R = −0.100, −0.602 and −0.683, respectively (Table 2).
The molecules that display a negative sign for the heat of formation parameter means that binding of these molecules with their protein targets may be spontaneous and do not require energy. The protein-ligand binding occurs only when the change in Gibbs free energy (ΔG: is the free energy that gives an indication about a binding affinity to the target site) of the system is negative. Furthermore, Hydrogen bonding is one of the important factors which is responsible for determining the three-dimensional structure of folded proteins including enzymes and the ligand molecule. Also, it is involved in determining the polarity and permeability of compounds. Calculations showed that antimycobacterial activity expressed in MIC (μg/mL) is negatively correlated with both hydrogen bond donor and hydrogen bond acceptor count. Calculation of the number of hydrogen bond donors, hydrogen bond acceptors, and other parameters of Lipinski’s (rule of five) showed that most of the target compounds presented drug-like characters [33,34,35].

2.2.3. Cytotoxic Study

Compounds 3, 4, 6h, 6i, 6l, 8g, and 8k displaying the lowest MIC values were selected for cytotoxicity test using model eukaryotic cell line (Vero) at the concentration range from 0.1 to 200 μg/mL with IC50 values more than 60 μg/mL. Compounds did not show a high cytotoxic effect on Vero cells (Table 3).
Notably, compound 4 which showed the lowest MIC value of 0.61 μg/mL also displayed very low cytotoxicity to Vero cells at all tested concentrations (0.1–200 μg/mL) with IC50 values close to 100 µg/mL (99.4) and accordingly its selectivity index (SI) value more than 10 (162.95), providing its promising potential in biomedical application. In the case of compounds 3, 6h, 6i, and 6l, a slight reduction in cell viability was observed with IC50 ranging from 80.7–95.5 µg/mL, whereas 8g and 8k showed the more pronounced cytotoxic effect was with IC50 72.3 and 68.6 µg/mL, respectively. Therefore, it may be assumed that 4, 6h, 6i, 6l, 8g, and 8k derivatives, which were non-toxic or showed very low toxicity at tested concentration range, are very promising and potentially safe antimycobacterial compounds.

2.2.4. Molecular Docking

The inhibitory profile of triclosan and compounds 3, 8g (models for the higher inhibitory activity) and 8b (model for the deleterious inhibitory activity) were chosen for further investigation by docking into InhA reductase active site (PDB code: 3FNH) to gain insight into the potential binding modes [36,37,38]. As a first step, for the validation of docking parameters, the co-crystal ligand (JPJ400) was re-docked at the catalytic site of the protein. The RMSD between co-crystal and re-docked poses was found to be 0.331 (<2A), which confirmed the validity of the docking parameters. Triclosan exploited two major interactions. Firstly, the hydrophilic interaction has been noticed by the hydroxyl OH via two hydrogen bonds i.e., the oxygen engaged with the hydrophilic side chainTyr158 while the hydrogen forms the second hydrogen bond with NAD. Secondly, clusters of hydrophobic interactions including pi—or thirteen—alkyl interactions with NAD, Phe97, Met161, Pro193, Ala198, Met199, and Ile202 were also found. Further, pi-cation interaction with NAD, pi-sulfur interaction with Met103 and also, pi-pi stacked interaction with Phe149 have been noticed as well (Figure 3).
By careful analysis of the docked poses of compounds 3 and 8g, it was clear that both compounds can occupy the same binding mode as Triclosan with binding interaction energy (−24.264) kcal/mol (for compound 3) to −17.148 kcal/mol (for compound 8g) compared to Triclosan (−22.507) kcal/mol. The hydrophilic interaction has been noticed in compound 3 via the carbonyl oxygen that forms a hydrogen bond with Tyr158 side chain, while the hydrogen of amino group forms the second one with NAD, but compound 8g was involved in only one i.e., N4 of the oxadiazole ring forms one hydrogen bond with the hydrophilic residue Tyr 158, likely due to its bulkiness and this may explain its low potency than compound 3 (Figure 4 and Figure 5). The hydrophobic interactions in compound 3 were incorporating three pi-alkyl interactions with Pro193, Met199 and Leu218. Moreover, two pi-sulfur interactions with Met155 and Met199, one attractive charge interaction with NAD and two pi-pi T-shaped interactions with Phe149 and Tyr158 have been observed. In the same mode, compound 8g displays its hydrophobic interactions with different amino acid residues that embodying five pi-pi stacked interactions with NAD, Phe97, and Phe149. Also, eight pi-alkyl interactions with Phe149, Met161, Ala198, Ala201, Ile215, and Leu218 were found.
It is worth pointing out that in compound 8b, the hydrogen of the hydrazide group showed unfavorable donor-donor interaction (red color) with binding interaction energy (+11.145) kcal/mol. Also, the compound has not involved in any hydrogen bonds and forms only hydrophobic interaction with some amino acid residues and this may reflect the low activity of the compound (Figure 6).

3. Material and Methods

3.1. Chemistry

Melting points were recorded on a Stuart SMP30 (Stuart, Cole-Parmer, Staffordshire, UK) melting point apparatus. IR spectra (KBr, cm−1) were recorded on a Vector 22FT-IR Fourier Transform infrared (FTIR) spectrometer (Bruker, Billerica, MA, USA). 1H-NMR and 13C-NMR spectra were recorded at 500 and 125 MHz, respectively, on an Inova 500 MHz spectrometer (Bruker, Billerica, MA, USA), using dimethyl sulphoxide (DMSO-d6)/deuterated chloroform (CDCl3) as a solvent and tetramethylsilane (TMS) as an internal standard (chemical shift in δ, ppm). Mass spectra were determined using a Shimadzu GC/MS QP 1000 EX system (Shimadzu Corporation, Tokyo, Japan) with ionization energy 70 eV. Elemental analysis were determined using an Automatic Elemental Analyzer CHN Model 2400 (Perkin Elmer, Richmond, CA, USA) at the Micro-analytical Center, Faculty of Science, Cairo University (Cairo, Egypt). All the results of elemental analyses corresponded to the calculated values within experimental error. Progress of the reaction was monitored by thin-layer chromatography (TLC) using precoated TLC sheets with ultraviolet (UV) fluorescent silica gel (60F254, Merck, Kenilworth, NJ, USA) and spots were visualized by iodine vapors or irradiation with UV light (254 nm). All the chemicals were purchased from Sigma-Aldrich Chemicals, St. Louis, MO, USA. Compounds 2, 3, 4, 6g, 6i–k and 8i–k were prepared according to the reported procedures [30,39,40].
Methyl 4-phenoxybenzoate (2). Concentrated H2SO4 (1.0 mL) was added dropwise to a solution of 4-phenoxybenzoic acid (3.3 g, 15.6 mmol) in methanol (25 mL). The reaction mixture was allowed to reflux for 8 h. The reaction mixture was concentrated under reduced pressure. The obtained residue was treated with 10% aqueous NaHCO3 (10 mL). Stirring was continued for 15 m. During which time, the precipitate was formed then collected by filtration then dried and purified by crystallization using methanol to afford white solid in 80% yield; m.p. 159–160 °C; 1H-NMR (CDCl3) δ: 3.90 (s, 3H, OCH3), 6.99 (d, J = 8.8 Hz, 2H, ArH), 7.07 (d, J = 7.8 Hz, 2H, ArH), 7.19 (t, J = 7.9 Hz, 1H, ArH), 7.39 (t, 2H, J = 7.9 Hz, ArH), 8.00 (d, J = 8.4 Hz, 2H, ArH); 13C-NMR (CDCl3) δ: 52.1 (OCH3), 117.4(C3, C5), 120.2 (C3′, C5′), 124.6 (C1), 130.2 (C2′, C6′), 131.8 (C2, C6), 155.8 (C4), 162.0 (C1′), 166.7 (C4′), 207.1 (C=O).
4-Phenoxybenzohydrazide (3). Methyl 4-phenoxybenzoate (228 mg, 1 mmol) was added to a solution of hydrazine hydrate 98% (0.5 mL) in ethanol (5 mL). The mixture was refluxed for 2 h. The reaction mixture was evaporated under vacuum, water (10 mL) was added to the obtained residue. The obtained mixture was extracted with ethyl acetate (2 × 10 mL). The combined organic layers were then washed with a saturated solution of sodium bicarbonate and (1 × 10 mL) then brine (1 × 10 mL) before being dried (MgSO4). The obtained filtrate was concentrated under reduced pressure, filtered off and the precipitate was subjected to crystallization using EtOAc/petroleum ether. White solid, Yield: 84%; m.p.: 180–190 °C; 1H-NMR (CDCl3) δ: 4.49 (s, 2H, NH2), 7.00 (d, J = 8.0 Hz, 2H, ArH), 7.05 (d, J = 8.0 Hz, 2H, ArH), 7.18 (t, J = 7.5 Hz, 1H, ArH), 7.36–7.40 (m, 2H, ArH), 7.41 (s, 1H, NH), 7.72 (d, J = 8.2 Hz, 2H, ArH). 13C-NMR (CDCl3) δ: 118.0 (C3, C5), 120.1 (C3′, C5′), 124.6 (C1), 127.1 (C1′), 128.9 (C2′, C6′), 130.2 (C2, C6), 155.9 (C4), 161.1 (C4′), 168.3 (C=O).
2-(4-Phenoxyphenyl)-1,3,4-oxadiazole (4). A mixture of hydrazide 3 (1 mmol) and triethyl orthoformate (2 mL) were refluxed for 3 h. The reaction mixture was concentrated under vacuum; the residue was cooled and then treated with hexane (5 mL). The obtained precipitate was filtered off and recrystallized from ethanol/water (1:1). White solid, Yield: 73%; m.p. 140–144 °C [26]. 1H-NMR (DMSO-d6) δ: 7.14–7.17 (m, 4H, ArH), 7.25 (t, J = 7.5 Hz, 1H ArH), 7.45–7.49 (m, 2H, ArH), 8.01–8.04 (m, 2H, ArH), 9.31 (s, 1H, CH-oxadiazole). 13C-NMR (DMSO-d6) δ: 117.8 (C3, C5), 118.3 (C3′, C5′), 119.9 (C1), 124.7 (C1′), 128.9 (C2, C6), 130.3 (C2′, C6′), 154.2 (C4′), 155.1 (C4), 160.2 (C=N), 163.3 (C=N). Anal. Calcd. for C14H10N2O2: C, 70.58; H, 4.23; N, 11.76. Found: C, 70.50; H, 4.48; N 11.37.
2-(4-Phenoxyphenyl)-5-phenyl-1,3,4-oxadiazole (6a). White solid, Yield; 70%; m.p. 233–235 °C. 1H-NMR (CDCl3) δ: 7.01–7.07 (m, 5H, ArH), 7.18–7.22 (m, 1H, ArH), 7.38–7.56 (m, 5H, ArH), 7.85–7.88 (m, 3H, ArH). 13C-NMR (CDCl3) δ: 118.0 (C3, C5), 119.1 (C3′, C5′), 120.3 (C3″), 122.9 (C5″), 124.8 (C1), 125.7 (C1′, C1″), 127.5 (C2, C6), 129.1 (C2′, C6′), 129.5 (C2″), 130.3 (C6″), 131.6 (C4), 132.7 (C4′), 161.7, (C4″), 164.3 (C=N), 164.5 (C=N). Anal. Calcd for C20H14N2O2: C, 76.42; H, 4.49; N, 8.91. Found: C, 76.54; H, 4.23; N 9.27.
2-(4-Phenoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazole (6b). White solid, Yield; 76%, m.p. 250–253 °C. 1H-NMR (CDCl3) δ: 3.92 (s, 3H, OMe), 3.97 (s, 6H, 2OMe), 7.05 (d, J = 8.0 Hz, 2H, ArH), 7.18–7.24 (m, 3H, ArH), 7.34 (s, 2H, ArH), 7.64–7.70 (m, 2H, ArH), 7.98 (d, J = 8.2 Hz, 2H, ArH). 13C-NMR (CDCl3) δ: 56.7 (OMe), 56.8 (OMe), 61.3 (OMe), 104.4 (C3, C5), 104.7 (C3′, C5′), 118.5 (C3″, C5″), 119.2 (C1, C1′), 120.2 (C1″), 124.8 (C2, C6), 129.1 (C2′, C6′), 130.3 (C2″, C6″), 141.4 (C4), 153.9 (C4′), 155.9 (C4″), 161.0 (C=N), 162.4 (C=N). Anal. Calcd for C23H20N2O5: C, 68.31; H, 4.98; N 6.93. Found: C, 67.92; H, 5.02; N 7.05.
2-(4-Methoxyphenyl)-5-(4-phenoxyphenyl)-1,3,4-oxadiazole (6c). White solid, Yield; 72%, m.p.: 226–228 °C. 1H-NMR (CDCl3) δ: 3.87 (s, 3H, OMe), 7.00–7.02 (m, 2H, ArH), 7.10–7.20 (m, 4H, ArH), 7.17–7.20 (m, 1H, ArH), 7.37–7.40 (m, 2H, ArH), 8.03–8.07 (m, 4H, ArH). 13C-NMR (CDCl3,) δ: 55.7 (OMe), 114.8 (C3, C5), 116.7 (C3′, C5′), 118.5 (C3″, C5″), 118.7 (C1), 120.2 (C1′), 124.7 (C2, C6), 128.89 (C2′, C6′), 128.93 (C2″), 130.27 (C6″), 156.0 (C4), 160.9 (C4′), 162.6 (C4″), 1624.0 (C=N), 166.6 (C=N). Anal. Calcd for C21H16N2O3: C, 73.24; H, 4.68; N 8.13. Found: C, 73.62; H, 4.93; N 8.06.
2-(4-Nitrophenyl)-5-(4-phenoxyphenyl)-1,3,4-oxadiazole (6d). White solid, Yield; 77%, m.p.: 226–228°C. 1H-NMR (CDCl3) δ: 7.09–7.13 (m, 4H, ArH), 7.19–7.24 (m, 1H, ArH), 7.42 (dd, J = 15.8, 8.0 Hz, 2H, ArH), 7.42 (dd, J = 16.0, 8.0 Hz, 2H, ArH), 8.28–8.45 (m, 4H, ArH). 13C-NMR (CDCl3) δ: 118.5 (C3), 120.2 (C5), 120.4 (C3′), 124.7 (C5′), 124.8 (C3″), 125.0 (C5″), 128.0 (C1), 129.0 (C1′), 129.3 (C1″), 129.7 (C2), 130.3 (C6), 130.4 (C2′, C6′), 149.7 (C2″, C6″) 155.6 (C4), 155.9 (C4′), 161.0 (C4″), 161.6 (C=N), 162.8 (C=N). Anal. Calcd for C20H13N3O4: C, 66.85; H, 3.65; N, 11.69. Found: C, 66.73; H, 3.39; N 11.92.
2-(4-Chlorophenyl)-5-(4-phenoxyphenyl)-1,3,4-oxadiazole (6e). White solid, Yield; 72%, m.p.: 212–214 °C. 1H-NMR (CDCl3) δ: 7.09–7.11 (m, 4H, ArH), 7.20–7.21 (m, 1H, ArH), 7.40–7.43 (m, 2H, ArH), 7.51–7.53 (m, 3H, ArH), 8.06–8.09 (m, 4H, ArH). 13C-NMR (CDCl3) δ: 118.5 (C3), 120.2 (C5), 120.3 (C3′), 122.4 (C5′), 122.7 (C3″), 124.7 (C5″) 124.8 (C1), 128.4 (C1′), 128.5 (C1″), 129.0 (C2), 129.1 (C6), 129.7 (C2′), 129.8 (C6′), 130.28 (C2″), 130.30 (C6″), 138.2 (C4), 138.4 (C4′), 155.8 (C4″), 161.2 (C=N), 164.2 (C=N). Anal. Calcd for C20H13N3O4: C, 68.87; H, 3.76; N, 8.03. Found: C, 68.63; H, 3.40; N 8.23.
2-(4-(Benzyloxy)phenyl)-5-(4-phenoxyphenyl)-1,3,4-oxadiazole (6f). White solid, Yield; 80%, m.p.: 226–229 °C. 1H-NMR (DMSO-d6) δ: 5.14 (s, 2H, OCH2-), 7.03 (d, J = 8.3 Hz, 2H, ArH), 7.06 (d, J = 8.1 Hz, 2H, ArH), 7.12 (t, J = 11.5 Hz, 2H, ArH), 7.34–7.45 (m, 8H, ArH), 7.99 (d, J = 8.6 Hz, 2H, ArH), 8.10 (d, J = 9.1 Hz, 2H, ArH). 13C-NMR (DMSO-d6) δ: 70.9 (OCH2-), 114.6 (C3, C5) 114.8 (C3′, C5′), 115.7 (C3″), 118.0 (C5″), 118.6 (C3‴, C5‴), 121.3 (C1, C1′), 127.4 (C1″, C1‴), 128.2 (C2, C6), 128.8 (C2′), 129.1 (C6′), 131.2 (C2″, C6″), 136.7 (C2‴, C6‴), 153.5 (C4, C4′), 155.2 (C4″), 157.3 (C4‴), 165.7 (C=N), 166.4 (C=N). Anal. Calcd for C27H20N2O3: C, 77.13; H, 4.79; N, 6.66. Found: C, 77.53; H, 4.60; N 6.24.
2-(Naphthalen-1-yl)-5-(4-phenoxyphenyl)-1,3,4-oxadiazole (6g). White solid, Yield; 70%, m.p.: 173–175 °C. 1H-NMR (CDCl3) δ: 7.11–7.15 (m, 2H, ArH), 7.20–7.23 (m, 1H, ArH), 7.40–7.44 (m, 1H, ArH), 7.59–7.64 (m, 3H, ArH), 7.69–7.75, (m, 1H, ArH), 7.49–8.09 (m, 3H, ArH), 8.16 (d, J = 8.0 Hz, 1H, ArH), 8.26 (d, J = 7 Hz, 1H, ArH), 8.35 (d, J = 7 Hz, 1H, ArH), 9.28 (d, J = 8.5 Hz, 1H, ArH), 9.38 (d, J = 8.5 Hz, 1H, ArH). 13C-NMR (CDCl3) δ: 118.6, 120.2, 120.8, 124.8, 125.1, 126.5, 127.0, 128.45, 128.50, 128.8, 128.9, 129.2, 130.3, 132.7, 132.9, 134.1, 134.2, 155.9, 161.1 (Ar-C), 164.1 (C=N), 164.6 (C=N). Anal. Calcd for C24H16N2O2: C, 79.11; H, 4.43; N, 7.69. Found: C, 78.93; H, 4.40; N 8.01.
2-(4-Phenoxyphenyl)-5-(pyridin-3-yl)-1,3,4-oxadiazole (6h). White solid, Yield; 70%, m.p.: 143–144 °C. 1H-NMR (DMSO-d6) δ: 7.03 (d, J = 7.5 Hz, 2H, ArH), 7.06 (d, J = 8.2 Hz, 2H, ArH), 7.19–7.22 (m, 3H, ArH), 7.39 (t, J = 9.0 Hz, 2H, ArH), 7.98 (d, J = 7.5 Hz, 2H, ArH), 8.83 (d, J = 8.0 Hz, 2H, ArH); 13C-NMR (DMSO-d6) δ: 114.9 (C3, C5), 115.1 (C3′, C5′), 118.3 (C5″-pyridyl), 120.5 (C1, C1′), 121.6 (C1″-pyridyl), 123.5 (C2, C6), 127.3 (C2′, C6′), 129.4 (C6″-pyridyl), 131.2 (C4), 132.45 (C4′-pyridyl), 151.07 (C2=N pyridyl, C4=N-pyridyl), 162.92 (C=N), 165.62 (C=N). Anal. Calcd for C19H13N3O2: C, 72.37; H, 4.16; N, 13.33. Found: C, 72.66; H, 4.39; N 13.65.
2-(4-Phenoxyphenyl)-5-(pyridin-4-yl)-1,3,4-oxadiazole (6i). White solid, Yield; 70%, m.p.: 125–127 °C. 1H-NMR (CDCl3) δ: 7.05–7.16 (m, 6H, ArH), 7.22–7.26 (m, 1H, ArH), 7.41–7.45 (m, 3H, ArH), 8.08–8.15 (m, 3H, ArH). 13C-NMR (CDCl3) δ: 117.5 (C3), 117.6 (C5), 117.9 (C3′), 118.2 (C5′), 118.5 (C2, C6-pyridyl), 120.4 (C1), 120.5 (C1′), 120.7 (C1″-pyridyl), 124.9 (C2), 129.5 (C6), 130.3 (C2′), 130.4 (C6′), 131.1 (C4), 132.6 (C4′), 133.1 (C3=N pyridyl), 134.4 (C5=N pyridyl), 162.7 (2C=N). Anal. Calcd for C19H13N3O2: C, 72.37; H, 4.16; N, 13.33. Found: C, 72.54; H, 4.40; N 13.43.
2-(Furan-2-yl)-5-(4-phenoxyphenyl)-1,3,4-oxadiazole (6j). White solid, Yield; 77%, m.p.: 129–132 °C. 1H-NMR (CDCl3) δ: 6.65 (s, 1H, ArH), 7.11–7.13 (m, 4H, ArH), 7.23–7.25 (m, 2H, ArH), 7.44 (t, J = 8.01, 2H, ArH), 7.70 (s, 1H, ArH), 8.10 (d, J = 8.0 Hz, 2H, ArH). 13C-NMR (CDCl3) δ: 112.4 (C3), 114.2 (C5), 118.1 (C3′), 118.5 (C5′), 120.2 (C1), 120.3 (C1′), 124.8 (C2-furfuryl), 129.0 (C5-furfuryl), 129.2 (C3, C4 furfuryl), 130.3 (C2, C6), 139.8 (C2′), 145.9 (C6′), 155.8 (C4), 157.5 (C4′), 161.2 (C=N), 163.9 (C=N). Anal. Calcd for C18H12N2O3: C, 71.05; H, 4.67; N, 9.21. Found: C, 71.36; H, 4.39; N 9.55.
2-(4-Phenoxyphenyl)-5-(thiophen-2-yl)-1,3,4-oxadiazole (6k). White solid, Yield; 75%, m.p.: 139–141 °C. 1H-NMR (CDCl3) δ: 6.80–6.93 (m, 4H, ArH), 7.09–7.11 (m, 2H, ArH), 7.19–7.22 (m, 1H, ArH), 7.47–7.35 (m, 1H, ArH), 8.07–8.09 (m, 1H, ArH), 7.81–7.83 (m, 1H, ArH). 13C-NMR (CDCl3) δ: 118.2 (C3), 118.4 (C5), 120.2 (C3′), 124.7 (C5′), 125.4 (C1), 128.3 (C1′), 128.9 (C2, C5-thienyl), 129.0 (C3, C4-thienyl), 129.8 (C2), 130.0 (C6), 130.19 (C2′), 130.21 (C6′), 130.4 (C4), 155.8 (C4′), 161.0 (C=N), 163.9 (C=N). Anal. Calcd for C18H12N2O2S: C, 67.48; H, 3.78; N, 8.74. Found: C, 67.35; H, 3.36; N 9.02.
2,5-bis(4-Phenoxyphenyl)-1,3,4-oxadiazole (6l). White solid, Yield; 85%, m.p.: 232–234 °C. 1H-NMR (CDCl3) δ: 6.95–7.12 (m, 9H, ArH), 7.17–7.24 (m, 2H, ArH), 7.32–7.40 (m, 4H, ArH), 8.04–8.406 (m, 3H, ArH). 13C-NMR (CDCl3) δ: 118.1, 118.5, 118.6, 118.9, 119.3, 119.5, 120.2, 123.9, 124.7, 129.0, 129.5, 129.8, 130.0, 130.3, 155.9 (Ar-C) 160.9 (C=N), 164.2 (C=N). Anal. Calcd for C26H18N2O3: C, 76.83; H, 4.46; N, 6.89. Found: C, 77.01; H, 4.60; N 6.74.
(E)-N′-Benzylidene-4-phenoxybenzohydrazide (8a). White solid, Yield; 89%, m.p.: 163–165 °C. 1H-NMR (DMSO-d6) δ: 7.08–7.12 (m, 4H, ArH), 7.12–7.24 (m, 1H, ArH), 7.44–7.47 (m, 5H, ArH), 7.73 (d, J = 6.9 2H, ArH), 7.96 (d, J = 8.2 Hz, 2H, ArH), 8.46 (s, 1H, CH=N), 11.82 (s, 1H, NH). 13C-NMR (DMSO-d6) δ: 117.5 (C3, C5), 119.6 (C3′, C5′), 124.4 (C3″, C5″), 127.1 (C1, C1′), 127.9 (C1″), 128.8 (C2, C6), 128.9 (C2′, C6′), 130.0 (C2″), 130.3 (C6″), 134.4 (C4), 147.5 (C4′), 155.5 (C4″), 159.9 (C=O), 162.4 (C=N). Anal. Calcd for C20H16N2O2: C, 75.93; H, 5.10; N, 8.86. Found: C, 75.54; H, 5.32; N 9.11.
(E)-4-Phenoxy-N′-(3,4,5-trimethoxybenzylidene)benzohydrazide (8b). White solid, Yield; 92%, m.p.: 191–192 °C. 1H-NMR (DMSO-d6) δ: 3.71 (s, 3H, OMe), 3.84 (s, 6H, 2OMe), 7.03 (s, 2H, ArH), 7.10 (d, J = 7.9 Hz, 4H, ArH), 7.21–7.24 (m, 1H, ArH), 7.45 (t, J = 7.9 Hz, 2H, ArH), 7.95 (d, J = 8.0 Hz, 2H, ArH), 8.39 (s, 1H, CH=N), 11.80 (s, 1H, NH). 13C-NMR (DMSO-d6) δ: 55.9 (OMe), 602.1 (2OMe), 104.3 (C3, C5), 117.5 (C3′, C5′), 119.6 (C3″, C5″), 124.4 (C1, C1′), 128.0 (C1″), 129.9 (C2, C6), 130.3 (C2′, C6′), 139.2 (C2″, C6″), 147.6 (C4), 153.2 (C4′), 155.5 (C4″), 159.9 (C=O), 162.4 (C=N). Anal. Calcd for C23H22N2O5: C, 67.97; H, 5.46; N, 6.89. Found: C, 67.92; H, 5.32; N 7.02.
(E)-N′-(4-Methoxybenzylidene)-4-phenoxybenzohydrazide (8c). White solid, Yield; 92%, m.p.: 233–235 °C. 1H-NMR (DMSO-d6) δ: 3.81 (s, 3H, OMe), 7.02 (d, J = 8.4, 2H, ArH), 7.08–7.12 (m, 4H, ArH), 7.22 (t, J = 7.5 Hz, 1H, ArH), 7.45 (t, J = 8.0 Hz, 2H, ArH), 7.67 (d, J = 8.0 Hz, 2H, ArH), 7.95 (d, J = 8.2 Hz, 2H, ArH), 8.40 (s, 1H, CH=N), 11.68 (s, 1H, NH). 13C-NMR (DMSO-d6) δ: 55.3 (OMe), 114.3 (C3, C5), 117.5 (C3′, C5′), 119.6 (C3″, C5″), 124.4 (C1, C1′), 126.9 (C1″), 128.1 (C2, C6), 128.6 (C2′, C6′), 129.8 (C2″), 130.3 (C6″), 147.4 (C4), 155.5 (C4′), 159.8 (C4″), 160.8 (C=O), 162.2 (C=N). Anal. Calcd for C21H18N2O3: C, 72.82; H, 5.24; N, 8.09. Found: C, 72.72; H, 5.53; N 8.06.
(E)-N′-(4-Chlorobenzylidene)-4-phenoxybenzohydrazide (8d). White solid, Yield; 92%, m.p.: 184–186 °C. 1H-NMR (DMSO-d6) δ: 7.06 (d, J = 7 Hz, 2H, ArH), 7.09 (d, J = 7.5 Hz, 2H, ArH), 7.22 (t, J = 11.5 Hz, 2H, ArH), 7.44 (t, J = 12.0 Hz, 3H, ArH), 7.99 (d, J = 8.4 Hz, 2H, ArH), 8.10 (d, J = 9.2 Hz, 2H, ArH), 8.77 (s, 1H, CH=N), 11.86 (s, 1H, NH). 13C-NMR (DMSO-d6) δ: 117.5 (C3, C5), 119.6 (C3′, C5′), 124.4 (C3″, C5″), 127.8 (C3‴, C5‴), 128.7 (C1, C1′), 128.9 (C1″, C1‴), 129.9 (C2, C6), 130.3 (C2′, C6′), 133.3 (C2″, C6″), 134.4 (C2‴, C6‴), 146.2 (C4, C4′), 155.4 (C4″, C4‴), 160.0 (C=O), 162.5 (C=N). Anal. Calcd for C20H15ClN2O2: C, 68.48; H, 4.31; N, 7.99. Found: C, 68.37; H, 4.40; N 8.33.
(E)-N′-(4-Chlorobenzylidene)-4-phenoxybenzohydrazide (8e). White solid, Yield; 92%, m.p.: 184–186 °C. 1H-NMR (DMSO-d6) δ: 7.09–7.12 (m, 4H, ArH), 7.23 (t, J = 7.5 Hz, 2H, ArH), 7.45 (t, J = 7.5 Hz, 2H, ArH), 7.97 (d, J = 8.0 Hz, 4H, ArH), 8.29 (d, J = 8.4 Hz, 2H, ArH), 8.54 (s, 1H, CH=N), 12.10 (s, 1H, NH).13C-NMR (DMSO-d6) δ: 117.4 (C3, C5), 119.7 (C3′, C5′), 124.1 (C3″, C5″), 124.5 (C3‴, C5‴), 127.5 (C1, C1′), 127.9 (C1″, C1‴), 130.1 (C2, C6), 130.3 (C2′, C6′), 140.7 (C2″, C6″), 145.0 (C2‴, C6‴), 147.8 (C4, C4′), 148.8 (C4″), 155.4 (C4‴), 160.2 (C=O), 162.6 (C=N). Anal. Calcd for C20H15ClN2O2: C, 68.48; H, 4.31; N, 7.99. Found: C, 68.37; H, 4.40; N 8.33.
(E)-N′-[4-(Benzyloxy)benzylidene]-4-phenoxybenzohydrazide (8f). White solid, Yield; 93%, m.p.: 228–231 °C. 1H-NMR (DMSO-d6) δ: 5.17 (s, 2H, ArH), 7.08–7.12 (m, 6H, ArH), 7.21–7.24 (m, 1H, ArH), 7.33–7.48 (m, 7H, ArH), 7.67 (d, J = 8.7 Hz, 2H, ArH), 7.94 (d, J = 8.6 Hz, 2H, ArH), 8.39 (s, 1H, CH=N), 11.68 (s, 1H, NH). 13C-NMR (DMSO-d6) δ: 69. 4 (OCH2), 115.2 (C3), 117.5 (C5), 119.6 (C3′, C5′), 124.4 (C3″), 127.1 (C5″), 127.8 (C1), 127.9 (C1′), 128.1 (C1″), 128.5 (C2), 128.6 (C6), 129.8 (C2′, C6′), 130.3 (C2″, C6″), 136.8 (C4), 147.4 (C4′), 155.5 (C4″), 159.9 (C=O), 162.2 (C=N). Anal. Calcd for C27H22N2O3: C, 76.76; H, 5.25; N, 6.63. Found: C, 76.56; H, 5.60; N 6.34.
(E)-N′-(Naphthalen-1-ylmethylene)-4-phenoxybenzohydrazide (8g). White solid, Yield; 88%, m.p.: 193–195 °C. 1H-NMR (DMSO-d6) δ: 7.12–7.14 (m, 4H, ArH), 7.24 (t, J = 7.9 Hz, 2H, ArH), 7.45–7.48 (m, 2H, ArH), 7.60–7.62, (m, 2H, ArH), 7.63–7.69, (m, 1H, ArH), 7.93–7.95 (m, 1H, ArH), 8.01–8.04 (m, 4H, ArH), 8.87–8.89 (m, 1H, ArH), 9.11 (s, 1H, CH=N), 11.90 (s, 1H, NH). 13C-NMR (DMSO-d6) δ: 117.5, 119.6, 124.2, 124.4, 125.6, 126.3, 127.3, 127.7, 127.9, 128.8, 129.6, 129.9, 130.2, 130.3, 130.5, 133.5, 147.4, 155.5 (Ar-C), 160.0 (C=O), 162.3 (C=N). Anal. Calcd for C24H18N2O2: C, 78.67; H, 4.95; N, 7.65. Found: C, 78.92; H, 4.60; N 8.04.
(E)-4-Phenoxy-N′-(pyridin-3-ylmethylene)benzohydrazide (8h). White solid, Yield; 90%, m.p.: 149–151 °C. 1H-NMR (DMSO-d6) δ: 7.09–7.14 (m, 4H, ArH), 7.22–7.25 (m, 1H, ArH), 7.44–7.50 (m, 3H, ArH), 7.97 (d, J = 8.4 Hz, 2H, ArH), 8.14 (d, J = 7.0 Hz, 1H, ArH), 8.51 (s, 1H, CH=N), 8.62 (d, J = 8.3 Hz, 1H, ArH), 8.86 (d, J = 8.3 Hz, 1H, ArH), 11.98 (s, 1H, NH). 13C-NMR (DMSO-d6) δ: 117.5 (C3, C5), 119.6 (C3′, C5′), 124.0 (C5-pyridyl), 124.5 (C1), 127.7 (C1′), 130.0 (C1-pyridyl), 130.3 (C2, C6), 133.4 (C2′, C6′), 144.8 (C6-pyridyl), 148.7 (C4, C4′), 150.7 (C2=N pyridyl), 155.4 (C4=N pyridyl), 160.0 (C=O), 162.5 (C=N). Anal. Calcd for C19H15N3O2: C, 71.91; H, 4.76; N, 13.24. Found: C, 71.46; H, 4.54; N 13.55.
(E)-4-Phenoxy-N′-(pyridin-4-ylmethylene)benzohydrazide (8i). White solid, Yield; 92%, m.p.: 175–177 °C. 1H-NMR (DMSO-d6) δ: 7.10–7.13 (m, 4H, ArH), 7.24 (t, J = 8.2 Hz, 1H, ArH), 7.46 (t, J = 8.2 Hz, 2H, ArH), 7.67 (s, 2H, ArH), 7.97 (d, J = 7.9 Hz, 2H, ArH), 8.44 (s, 1H, CH=N), 8.66 (s, 2H, ArH), 12.08 (s, 1H, NH). 13C-NMR (DMSO-d6) δ: 117.5 (C3, C5), 119.7 (C3′, C5′), 121.0 (C5-pyridyl), 124.5 (C1, C1′), 127.5 (C1-pyridyl), 130.1 (C2, C6), 130.3 (C2′, C6′), 141.5 (C6-pyridyl), 145.0 (C4, C4′), 150.3 (C3=N pyridyl), 155.4 (C4=N pyridyl), 160.2 (C=O), 162.6 (C=N). Anal. Calcd for C19H15N3O2: C, 71.91; H, 4.76; N, 13.24. Found: C, 71.64; H, 4.60; N 13.42.
(E)-N′-(Furan-2-ylmethylene)-4-phenoxybenzohydrazide (8j). White solid, Yield; 89%, m.p.: 192–194 °C. 1H-NMR (DMSO-d6): δ 6.64 (s, 1H, ArH), 6.92 (s, 1H, ArH), 7.08–7.12 (m, 4H, ArH), 7.21–7.24 (m, 1H, ArH), 7.45 (t, J = 7.9 Hz, 2H, ArH), 7.85 (s, 1H, ArH), 7.93 (d, J = 7.9 Hz, 2H, ArH), 8.34 (s, 1H, CH=N), 11.75 (s, 1H, NH). 13C-NMR (DMSO-d6) δ: 112.2 (C3), 133.4 (C5), 117.5 (C3′, C5′), 119.6 (C3, C4–furfuryl), 124.4 (C1), 127.9 (C1′), 129.9 (C2, C6), 130.3 (C2′, C6′), 137.3 (C2—furfuryl), 145.1 (C5–furfuryl), 149.5 (C4), 155.5 (C4′), 159.9 (C=O), 162.3 (C=N). Anal. Calcd for C18H14N2O3: C, 70.58; H, 4.61; N, 9.15. Found: C, 70.37; H, 4.32; N 9.50.
(E)-4-Phenoxy-N′-(thiophen-2-ylmethylene)benzohydrazide (8k). White solid, Yield; 92%, m.p.: 182–183 °C. 1H-NMR (DMSO-d6) δ: 7.08–7.24 (m, 6H, ArH), 7.44–7.47 (m, 3H, ArH), 7.67 (d, J = 7.5 Hz, 1H, ArH), 7.93 (d, J = 7.0 Hz, 2H, ArH), 8.66 (s, 1H, CH=N), 11.76 (s, 1H, NH). 13C-NMR (DMSO-d6) δ: 117.5 (C3, C5), 119.6 (C3′, C5′), 124.4 (C3, C4 thienyl), 127.8 (C1) 128.8 (C1′), 128.8 (C2, C6), 129.8 (C2′), 130.3 (C6′) 130.8 (C4), 139.2 (C4′), 142.7 (C2–thienyl), 155.5 (C4–thienyl), 159.9 (C=O), 162.2 (C=N). Anal. Calcd for C18H14N2O2S: C, 67.06; H, 4.38; N, 8.69. Found: C, 67.36; H, 3.39; N 9.04.

3.2. Biology

3.2.1. In Vitro Anti-Tubercular Activity

The MICs of Compounds 3, 4, 6a–l, and 8a–k for M. tuberculosis H37Rv were determined by the microplate Alamar blue assay (MABA) (Table 1) [31,32]. Triclosan and INH were used as reference standards. M. tuberculosis H37Rv (ATCC 27294; American Type Culture Collection, Rockville, MD, USA) was grown to late log phase in Middlebrook 7H9 broth. Twofold dilutions of tested drugs were prepared in 7H9 broth in a volume of 100 μL in 96-well, clear-bottom microplates at a final testing concentration of 0.2, 0.4, 0.8, 1.6, 3.12, 6.25, 12.5, 25, 50 and 100 μg/mL. 100 μL of M. tuberculosis H37Rv (containing 2 × 104 CFU) was added, yielding a final testing volume of 200 μL. In each row, a drug-free (bacteria-only) control was added.
The plates were incubated at 37 °C; on the seventh day of incubation, 12.5 μL of 20% Tween 80 and 20 μL of Alamar blue were added to all wells. After incubation at 37 °C for 16 to 24 h, the fluorescence of the wells was read at an excitation of 530 nm and emission of 590 nm. The MIC was defined as the lowest concentration affecting a reduction in fluorescence of ≥90% relative to the mean of replicate bacteria-only controls.
Among the tested compounds, the results displayed that most of them i.e., 3, 4, 6h, 6i, 6l, 8g, and 8k showed promising anti-tubercular activity (MIC, 0.61–1.69 μg/mL) in comparison to triclosan (MIC, 10 μg/mL) and INH (MIC, 0.2 μg/mL).

3.2.2. In Vitro InhA Enzyme Inhibition

InhA enzyme assay was carried out utilizing a Cary100 Bio spectrophotometer (Agilent Technologies, Santa Clara, California, USA) at 25 °C, through monitoring the oxidation of NADH to NAD+ at 340 nm. Reactions were initiated via the addition of dodecenoyl-CoA (50 mm) substrate to mixtures containing InhA (5 nm), NADH (100 mm), and inhibitor (1–10,000 nm). The IC50 values were determined from a dose-response plot of enzyme fractional activity versus the concentration of inhibitor.

3.2.3. Cytotoxic Activity

The cytotoxicity test was carried out using Vero cell line (African green monkey kidney epithelial cells), obtained from American Type Culture Collection (ATCC). The cells were cultured according to ATCC recommendations as it was described earlier [41,42]. To evaluate cytotoxicity, 3 × 104 Vero cells were seeded in the wells of 96-multiwell plates in 100 µL of the complete culture medium. After 24 h incubation at 37 °C when the cells were well attached and achieved 90% confluence, the culture medium was replaced with 100 µL of derivative solutions, which were tested at the concentration range of 0.1–200 µg/mL. The stock solutions of the synthesized derivatives were prepared in DMSO and the tested concentrations were prepared by nine serial 2-fold dilutions. Vero cells were exposed to the compounds and rifampicin for 24 h and then cell viability was assessed by MTT assay (Sigma-Aldrich Chemicals, St. Louis, MO, USA). The IC50 value, which is defined as the concentration of the derivative causing reduction in cell viability by 50%, was calculated using GraphPad Prism 5, version 5.03 software. Selectivity/safety index (SI) for tested agents was determined using the formula: SI = IC50/MIC.

3.2.4. Docking Methodology

Discovery Studio 2.5 software (Accelrys Inc., San Diego, CA, USA) was used for docking analysis. Fully automated docking tool using “Dock ligands (CDOCKER)” protocol running on Intel (R) Core (TM) i32370 CPU @ 2.4 GHz, RAM Memory 2 GB under the Windows 7.0 system. The crystal structures of InhA reductase enzyme (PDB code: 3FNH) were downloaded from the protein data bank [36,37,38]. See the Supplementary Materials.

4. Conclusions

A set of diphenyl ether hydrazides and their cyclized oxadiazole analogs were designed and synthesized as triclosan analogs. The targeted compounds have been identified using spectroscopic data and elemental microanalysis. The antitubercular activity of the un-substituted oxadiazole 3 and the hydrazide 4 experienced the highest activity than triclosan as a reference drug. Arylated oxadiazoles 6i and 6l and arylidenes 8g and 8k showed potent antitubercular activity against Mycobacterium tuberculosis H37Rv strains. The InhA reductase enzymatic study supports the experimental data. We believe there is more than one mode of mechanisms are involved in the antimycobacterial property of the synthesized diphenyl ether derivatives. The obtained results from the in silico pharmacokinetic properties calculation showed that most of the target compounds exhibited drug-like characters. Taken together, a docking study has boosted that the higher activity of compounds 3, 4, and 8g could be further investigated as potential lead antimycobacterial candidates.

Supplementary Materials

The following are available online: general experimental data and NMR spectra.

Author Contributions

Conceptualization, T.S.I. and S.S.P.; Methodology, A.M.M.A.-M., E.S.T., A.M.M., A.N.K., R.M.B. and I.A.S.; Software, M.F.A.M.; Validation, T.S.I. and S.S.P.; Formal analysis, E.S., A.M.M., A.N.K., R.M.B. and I.A.S.; Investigation, T.S.I., E.S.T., M.A.A., and S.S.P.; Resources, H.Z.A., N.A.A.; Data curation, T.S.I. and S.S.P.; Writing—original draft preparation, T.S.I., E.S.T., M.F.A.M. and S.S.P.; Writing—review and editing, T.S.I., E.S.T. and S.S.P.; Visualization, T.S.I. and S.S.P.; Supervision, T.S.I. and S.S.P.; Project administration, H.Z.A., N.A.A.; Funding acquisition, H.Z.A., N.A.A. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by King Abdulaziz University, Jeddah, under grant No. (RG-009-166-38).

Acknowledgments

The authors gratefully acknowledge DSR, King Abdulaziz University, Jeddah, for technical and financial support No. (RG-009-166-38).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. World Health Organization. Global Tuberculosis Report. 2015. Available online: www.who.int/tb/publications/global_report/gtbr15_main_text.pdf (accessed on 27 January 2020).
  2. World Health Organization. Global Tuberculosis Report. 2019. Available online: https://www.who.int/news-room/events/detail/2019/03/24/default-calendar/world-tb-day-2019 (accessed on 27 January 2020).
  3. Matteelli, A.; Roggi, A.; Carvalho, A.C. Extensively drug-resistant tuberculosis: Epidemiology and management. Clin. Epidemiol. 2014, 6, 111–118. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Chollet, A.; Maveyraud, L.; Lherbet, C.; Bernardes-Genisson, V. An overview on crystal structures of InhA protein: Apo-form, in complex with its natural ligands and inhibitors, Eur. J. Med. Chem. 2018, 146, 318–343. [Google Scholar] [CrossRef]
  5. Ende, C.W.A.; Knudson, S.E.; Liu, N.; Childs, J.; Sullivan, T.J.; Boyne, M.; Xu, H.; Gegina, Y.; Knudson, D.L.; Johnson, F.; et al. Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 3029–3033. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Perozzo, R.; Kuo, M.; Sidhu, A.B.S.; Valiyaveetti, J.T.; Bittman, R.; Jacobs, W.R., Jr.; Fidock, D.A.; Sacchettini, J.C.J. Structural Elucidation of the Specificity of the Antibacterial Agent Triclosan for Malarial Enoyl Acyl Carrier Protein Reductase. Biol. Chem. 2002, 277, 13106–13114. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Sharma, S.; Ramya, T.N.C.; Surolia, A.; Surolia, N. Triclosan as a Systemic Antibacterial Agent in a Mouse Model of Acute Bacterial Challenge. Antimicrob. Agents Chemother. 2003, 47, 3859–3866. [Google Scholar] [CrossRef] [Green Version]
  8. Chhibber, M.; Kumar, G.; Parasuraman, P.; Ramya, T.N.; Surolia, N.; Surolia, A. Novel diphenyl ethers: Design, docking studies, synthesis and inhibition of enoyl ACP reductase of Plasmodium falciparum and Escherichia coli. Bioorg. Med. Chem. 2006, 14, 8086–8098. [Google Scholar] [CrossRef]
  9. Mishra, S.; Karmodiya, K.; Parasuraman, P.; Surolia, A.; Surolia, N. Design, synthesis, and application of novel triclosan prodrugs as potential antimalarial and antibacterial agents. Bioorg. Med. Chem. Lett. 2008, 16, 5536–5546. [Google Scholar] [CrossRef]
  10. Butler, M.S.; Cooper, M.A.J. Antibiotics in the clinical pipeline in 2011. J. Antibiot. 2011, 64, 413–425. [Google Scholar] [CrossRef] [PubMed]
  11. Tonge, P.J.; Kisker, C.; Slayden, R.A. Development of Modern InhA Inhibitors to Combat Drug Resistant Strains of Mycobacterium tuberculosis. Curr. Top. Med. Chem. 2007, 7, 489–498. [Google Scholar] [CrossRef]
  12. Kini, S.G.; Bhat, A.R.; Bryant, B.; Williamson, J.S.; Dayan, F.E. Synthesis, antitubercular activity and docking study of novel cyclic azole substituted diphenyl ether derivatives. Eur. J. Med. Chem. 2009, 44, 492–500. [Google Scholar] [CrossRef]
  13. Kini, S.G.; Bhat, A.R.; Pan, Z.; Dayan, F.E. Synthesis and antitubercular activity of heterocycle substituted diphenyl ether derivatives. J. Enzyme Inhib. Med. Chem. 2010, 25, 730–736. [Google Scholar] [CrossRef] [PubMed]
  14. Sivaraman, S.; Sullivan, T.J.; Johnson, F.; Novichenok, P.; Cui, G.; Simmerling, C.; Tonge, P.J. Inhibition of the Bacterial Enoyl Reductase FabI by Triclosan:  A Structure−Reactivity Analysis of FabI Inhibition by Triclosan Analogues. J. Med. Chem. 2004, 47, 509–518. [Google Scholar] [CrossRef] [PubMed]
  15. Heath, R.J.; Yu, Y.T.; Shapiro, M.A.; Olson, E.; Rock, C.O. Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis. J. Biol. Chem. 1998, 273, 30316–30320. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Yang, Y.H.; Wang, Z.L.; Yang, J.Z.; Yang, T.; Pi, W.Y.; Ang, W.; Lin, Y.N.; Liu, Y.Y.; Li, Z.C.; Luo, Y.F.; et al. Design, synthesis and evaluation of novel molecules with a diphenyl ether nucleus as potential antitubercular agents. Bioorg. Med. Chem. Lett. 2012, 22, 954–957. [Google Scholar] [CrossRef] [PubMed]
  17. Navarrete-Vazquez, G.; Molina-Salinas, G.M.; Duarte-Fajardo, Z.V.; Vargas-Villarreal, J.; Estrada-Soto, S.; Gonzalez-Salazar, F.; Hernandez-Nunez, E.; Said-Fernandez, S. Synthesis and antimycobacterial activity of 4-(5-substituted-1,3,4-oxadiazol-2-yl)pyridines. Bioorg. Med. Chem. 2007, 15, 5502–5508. [Google Scholar] [CrossRef] [PubMed]
  18. Khan, R.H.; Rastogi, R.C. Synthesis of some 2-[(5-aryl-1,3,4-oxadiazol-2-yl)amino]-1,3-heterazoles as potential pesticides. J. Agric. Food Chem. 1990, 38, 1068–1071. [Google Scholar] [CrossRef]
  19. Narayana, B.; Raj, K.K.V.; Ashalatha, B.V.; Kumari, N.S. Synthesis of Some New 2-(6-Methoxy-2-Naphthyl)-5-Aryl-1,3,4-Oxadiazoles as Possible Non-steroidal Anti-inflammatory and Analgesic Agents. Arch. Pharm. Chem. Life Sci. 2005, 338, 373–377. [Google Scholar] [CrossRef]
  20. Rasras, A.J.M.; Al-Tel, T.H.; Al-Aboudi, A.F.; Al-Qawasmeh, R.A. Synthesis and antimicrobial activity of cholic acid hydrazone analogues. Eur. J. Med. Chem. 2010, 45, 2307–2313. [Google Scholar] [CrossRef]
  21. Mohareb, R.M.; Fleita, D.H.; Sakka, O.K. Novel Synthesis of Hydrazide-Hydrazone Derivatives and Their Utilization in the Synthesis of Coumarin, Pyridine, Thiazole and Thiophene Derivatives with Antitumor Activity. Molecules 2011, 16, 16–27. [Google Scholar] [CrossRef] [Green Version]
  22. Cascioferro, S.; Attanzio, A.; Di Sarno, V.; Musella, S.; Tesoriere, L.; Cirrincione, G.; Diana, P.; Parrino, B. New 1,2,4-Oxadiazole Nortopsentin Derivatives with Cytotoxic Activity. Mar. Drugs 2019, 17, 35. [Google Scholar] [CrossRef] [Green Version]
  23. Rollas, S.; Küçükgüzel, S.G. Biological Activities of Hydrazone Derivatives. Molecules 2007, 12, 1910–1939. [Google Scholar] [CrossRef] [Green Version]
  24. Asif, M. Pharmacologically potentials of hydrazonone containing compounds: A promising scaffold. Int. J. Adv. Chem. 2014, 2, 85–103. [Google Scholar] [CrossRef] [Green Version]
  25. Oliveira, P.F.M.; Guidetti, B.; Chamayou, A.; André-Barrès, C.; Madacki, J.; Korduláková, J.; Mori, G.; Orena, B.S.; Chiarelli, L.R.; Pasca, M.R.; et al. Mechanochemical Synthesis and Biological Evaluation of Novel Isoniazid Derivatives with Potent Antitubercular Activity. Molecules 2017, 22, 1457. [Google Scholar] [CrossRef]
  26. Freundlich, J.S.; Wang, F.; Vilcheze, C.; Gulten, G.; Langley, R.; Schiehser, G.A.; Jacobus, D.R.; Jacobs, W.R.; Sacchettini, J.C. Triclosan derivatives: Towards potent inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis. Chem. Med. Chem. 2009, 4, 241–248. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Ibrahim, H.R.; Tatsumoto, S.; Ono, H.; Van Immerseel, F.; Raspoet, R.; Miyata, T. A novel antibiotic-delivery system by using ovotransferrin as targeting molecule. Eur. J. Pharm. Sci. 2015, 66, 59–69. [Google Scholar] [CrossRef] [PubMed]
  28. Haga, N.; Takayanagi, H. Mechanisms of the Photochemical Rearrangement of Diphenyl Ethers. J. Org. Chem. 1996, 61, 735–745. [Google Scholar] [CrossRef]
  29. He, L.; Zhang, L.; Liu, X.; Li, X.; Zheng, M.; Li, H.; Yu, K.; Chen, K.; Shen, X.; Jiang, H.; et al. Discovering Potent Inhibitors Against the β-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) of Helicobacter pylori: Structure-Based Design, Synthesis, Bioassay, and Crystal Structure Determination. J. Med. Chem. 2009, 52, 2465–2481. [Google Scholar] [CrossRef]
  30. Ibrahim, T.S.; Al-Mahmoudy, A.M.; Elagawany, M.; Ibrahim, M.A.; Panda, S.S. Synthesis and Antiviral Bioassay of New Diphenyl Ether-based Compounds. Chem. Biol. Drug Des. 2016, 88, 511–518. [Google Scholar] [CrossRef]
  31. Collins, L.; Franzblau, S.G. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob. Agents Chemother. 1997, 41, 1004–1009. [Google Scholar] [CrossRef] [Green Version]
  32. Franzblau, S.G.; Witzig, R.S.; McLaughlin, J.C.; Torres, P.; Madico, G.; Hernandez, A.; Degnan, M.T.; Cook, M.B.; Quenzer, V.K.; Ferguson, R.M.; et al. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J. Clin. Microbiol. 1998, 36, 362–366. [Google Scholar] [CrossRef] [Green Version]
  33. Umaa, K.; Sudha Rani, S.; Sangeetha, G.; Maida Engels, S.E. Prediction of physiochemical parameters for anti-tubercular potentials of Mannich and Schiff bases. J. Chem. Pharm. Res. 2013, 5, 52–59. [Google Scholar]
  34. Lakshminarayana, S.B.; Huat, T.B.; Ho, P.C.; Manjunatha, U.H.; Dartois, V.; Dick, T.; Rao, S.P.S. Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents. J. Antimicrob. Chemother. 2015, 70, 857–867. [Google Scholar] [CrossRef] [PubMed]
  35. Wiener, H. Structural determination of Paraffin boiling point. J. Am. Chem. Soc. 1947, 69, 17–20. [Google Scholar] [CrossRef]
  36. Stec, J.; Vilchèze, C.; Lun, S.; Perryman, A.L.; Wang, X.; Freundlich, J.S.; Bishai, W.; Jacobs, W.R., Jr.; Kozikowski, A.P. Biological evaluation of potent triclosan-derived inhibitors of the enoyl-acyl carrier protein reductase InhA in drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis. Chem. Med. Chem. 2014, 9, 2528–2537. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  37. Mohamed, M.F.A.; Youssif, B.G.M.; Shaykoon, M.S.A.; Abdelrahman, M.H.; Elsadek, B.E.M.; Aboraia, A.S.; Abuo-Rahma, G.E.A. Utilization of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinone as a cap moiety in design of novel histone deacetylase inhibitors. Bioorg. Chem. 2019, 91, 103127. [Google Scholar] [CrossRef] [PubMed]
  38. Youssif, B.G.M.; Mohamed, M.F.A.; Al-Sanea, M.M.; Moustafa, A.H.; Abdelhamid, A.A.; Gomaa, H.A.M. Novel aryl carboximidamides and 3-aryl-1,2,4-oxadiazoles analogues of naproxen as dual selective COX-2 / LOX inhibitors: Design, synthesis and Docking studies. Bioorg. Chem. 2019, 85, 577–584. [Google Scholar] [CrossRef] [PubMed]
  39. Liu, Y.; Li, G.; Yang, L. Cu(I)-catalyzed Synthesis of Diaryl Ether Using a Simple Hydrazone as Promoter. Chin. J. Chem. 2009, 27, 423–427. [Google Scholar] [CrossRef]
  40. Bar-Yuan, H.; Kun-Ming, Y.; Yun, C. Synthesis of electroluminescent copoly(aryl ether)s containing alternate 1,4-distyrylbenzene derivatives and aromatic 1,3,4-oxadiazole or 3,3″-terphenyldicarbonitrile segments. J. Polym. Sci. Pol. Chem. 2005, 43, 5009–5022. [Google Scholar]
  41. Sieniawska, E.; Sawicki, R.; Swatko-Ossor, M.; Napiorkowska, A.; Przekora, A.; Ginalska, G.; Augustynowicz-Kopec, E. The effect of combining natural terpenes and antituberculous agents against reference and clinical Mycobacterium tuberculosis strains. Molecules 2018, 23, 176. [Google Scholar] [CrossRef] [Green Version]
  42. Trotsko, N.; Golus, J.; Kazimierczak, P.; Paneth, A.; Przekora, A.; Ginalska, G.; Wujec, M. Synthesis and antimycobacterial activity of thiazolidine-2,4-dione based derivatives with halogenbenzohydrazones and pyridinecarbohydrazones substituents. Eur. J. Med. Chem. 2020, 189, 112045. [Google Scholar] [CrossRef]
Sample Availability: Samples of the compounds 6a–l and 8a–k are available from the authors.
Molecules 25 03125 g001 550
Figure 1. Commercially available anti-tubercular drugs.
Figure 1. Commercially available anti-tubercular drugs.
Molecules 25 03125 g001
Molecules 25 03125 g002 550
Figure 2. Structures of triclosan, diphenyl ether, and hydrazone derivatives.
Figure 2. Structures of triclosan, diphenyl ether, and hydrazone derivatives.
Molecules 25 03125 g002
Molecules 25 03125 sch001 550
Scheme 1. Reagents and conditions: (i) Conc.H2SO4, MeOH, reflux, 8 h; (ii) NH2NH2.H2O, EtOH, reflux, 3 h.
Scheme 1. Reagents and conditions: (i) Conc.H2SO4, MeOH, reflux, 8 h; (ii) NH2NH2.H2O, EtOH, reflux, 3 h.
Molecules 25 03125 sch001
Molecules 25 03125 sch002 550
Scheme 2. Reagents and conditions: (i) Triethyl orthoformate reflux, 3 h; (ii) POCl3, reflux, 2–3 h; (iii) EtOH, reflux, 3–6 h.
Scheme 2. Reagents and conditions: (i) Triethyl orthoformate reflux, 3 h; (ii) POCl3, reflux, 2–3 h; (iii) EtOH, reflux, 3–6 h.
Molecules 25 03125 sch002
Molecules 25 03125 g003 550
Figure 3. Docking and binding mode of Triclosan into the active site of InhA reductase enzyme (PDB code: 3FNH). (A) 3D structure of triclosan (pink), (B) 2D structure of Triclosan (pink).
Figure 3. Docking and binding mode of Triclosan into the active site of InhA reductase enzyme (PDB code: 3FNH). (A) 3D structure of triclosan (pink), (B) 2D structure of Triclosan (pink).
Molecules 25 03125 g003
Molecules 25 03125 g004 550
Figure 4. Docking and binding mode of compound 3 into the active site of InhA reductase enzyme (PDB code: 3FNH). (A) 3D structure of compound 3 (green), (B) 2D structure of compound 3 (green).
Figure 4. Docking and binding mode of compound 3 into the active site of InhA reductase enzyme (PDB code: 3FNH). (A) 3D structure of compound 3 (green), (B) 2D structure of compound 3 (green).
Molecules 25 03125 g004
Molecules 25 03125 g005 550
Figure 5. Docking and binding mode of compound 8g into the active site of InhA reductase enzyme (PDB code: 3FNH). (A) 3D structure of compound 8g (blue), (B) 2D structure of compound 8g (blue).
Figure 5. Docking and binding mode of compound 8g into the active site of InhA reductase enzyme (PDB code: 3FNH). (A) 3D structure of compound 8g (blue), (B) 2D structure of compound 8g (blue).
Molecules 25 03125 g005
Molecules 25 03125 g006 550
Figure 6. Docking and binding mode of compound 8b into the active site of the InhA reductase enzyme (PDB code: 3FNH). (A) 3D structure of compound 8b (yellow), (B) 2D structure of compound 8b (yellow).
Figure 6. Docking and binding mode of compound 8b into the active site of the InhA reductase enzyme (PDB code: 3FNH). (A) 3D structure of compound 8b (yellow), (B) 2D structure of compound 8b (yellow).
Molecules 25 03125 g006
Table
Table 1. The antitubercular activity of the diphenyl ether derivatives against H37Rv strain of M. tuberculosis (MIC (μg/mL) and their inhibition for InhA reductase enzyme (IC50 µM).
Table 1. The antitubercular activity of the diphenyl ether derivatives against H37Rv strain of M. tuberculosis (MIC (μg/mL) and their inhibition for InhA reductase enzyme (IC50 µM).
ArNo.MIC (μg/mL)IC50 (µM)No.MIC (μg/mL)IC50 (µM)
----------30.863.4340.613.28
Molecules 25 03125 i0016a2.74>1008a34.5473.23
Molecules 25 03125 i0026b34.64>1008b50.20>100
Molecules 25 03125 i0036c39.04>1008c20.6875.46
Molecules 25 03125 i0046d15.1568.448d7.6719.75
Molecules 25 03125 i0056e15.8964.558e2.897.46
Molecules 25 03125 i0066f8.2341.248f22.6229.89
Molecules 25 03125 i0076g12.2333.828g0.984.23
Molecules 25 03125 i0086h1.405.088h6.9626.54
Molecules 25 03125 i0096i1.4011.728i6.8221.39
Molecules 25 03125 i0106j11.1251.428j6.3518.37
Molecules 25 03125 i0116k3.6578.658k1.695.61
Molecules 25 03125 i0126l1.175.63INH0.20ND
--------------------------------------Triclosan10.001.10
Table
Table 2. Correlation between calculated physicochemical parameters and biological activity.
Table 2. Correlation between calculated physicochemical parameters and biological activity.
Comp. No.MIC (μg/mL)Molecular MassBalaban IndexMolecular Topology: Wiener IndexTopological Diameter Bond (s)Molar Refractivity,
cm3/mol		Clog pHeat of Formation
[kJ/mol]		Gibbs Energy
[kJ/mol]
Energy		H Bond DonorH Bond AcceptorLipinski’s Rule
30.86228.250118,297586116.5892.231−60.70176.1423Yes
40.61238.250121,561682116.6562.753115.57339.7204Yes
6a2.74314.340400,2501561159.1674.806216.79493.0204Yes
6b34.64404.422110,77928281711.0184.427−276.20174.3907Yes
6c39.04344.37059,3221990179.7844.67952.46386.8105Yes
6d15.15359.34071,0662219179.778NDNDND05Yes
6e15.89348.770488,1621763169.6595.364189.58471.4604No
6f8.23420.470142,97137692112.2956.412165.15549.7405No
6g12.23364.404706,48223911710.8555.803313.83623.7204No
6h1.40315.332400,2501561158.9563.468270.22561.6505No
6i1.40315.332400,2501561158.9563.468270.22561.6505Yes
6j11.12304.305326,5961380148.3813.42174.450372.2005Yes
6k3.65320.06232,6591380148.9764.788251.71498.1804Yes
6l1.17406.440120,68633772011.8316.343185.97541.3205No
8a34.54384.390104,52028491910.9944.734145.52ND16Yes
8b50.20474.470250,73247532112.8454.354−347.47ND19Yes
8c20.68414.420145,70634972111.6114.607−18.810ND17Yes
8d7.67414.420145,70634972111.610ND−18.81ND17Yes
8e2.89418.84012,36031582011.4855.292118.31ND16Yes
8f22.62490.519301,09660232514.1226.33993.88ND17No
8g1.40434.450161,77040152012.6825.730242.56ND16No
8h6.96385.3801,045,201284919107833.396198.95ND17No
8i6.82385.3831,045,20128491910.7833.396198.95ND17Yes
8j6.35374.356880,34625661810.2083.3493.180ND17Yes
8k1.69390.41788,03425661810.8034.715180.44ND16Yes
R-0.308−0.1790.3150.260−0.1000.152−0.683−0.602−0.370−0.360-
Table
Table 3. MIC, IC50, and SI values determined for the selected most promising compounds.
Table 3. MIC, IC50, and SI values determined for the selected most promising compounds.
CompoundM. tuberculosisVero Cell LineSI (IC50/MIC)
MIC, µg/mLIC50 µg/mL ± SEM
30.8680.7 ± 1.3193.83
40.6199.4 ± 1.79162.95
6h1.4091.4 ± 1.5565.29
6i1.4095.5 ± 1.3668.21
6l1.1792.6 ± 1.8079.15
8g0.9872.2 ± 1.8773.67
6k1.6968.6 ± 1.1940.59

Share and Cite

MDPI and ACS Style

Ibrahim, T.S.; Taher, E.S.; Samir, E.; M. Malebari, A.; Khayyat, A.N.; Mohamed, M.F.A.; Bokhtia, R.M.; AlAwadh, M.A.; Seliem, I.A.; Asfour, H.Z.; et al. In Vitro Antimycobacterial Activity and Physicochemical Characterization of Diaryl Ether Triclosan Analogues as Potential InhA Reductase Inhibitors. Molecules 2020, 25, 3125. https://doi.org/10.3390/molecules25143125

AMA Style

Ibrahim TS, Taher ES, Samir E, M. Malebari A, Khayyat AN, Mohamed MFA, Bokhtia RM, AlAwadh MA, Seliem IA, Asfour HZ, et al. In Vitro Antimycobacterial Activity and Physicochemical Characterization of Diaryl Ether Triclosan Analogues as Potential InhA Reductase Inhibitors. Molecules. 2020; 25(14):3125. https://doi.org/10.3390/molecules25143125

Chicago/Turabian Style

Ibrahim, Tarek S., Ehab S. Taher, Ebtihal Samir, Azizah M. Malebari, Ahdab N. Khayyat, Mamdouh F. A. Mohamed, Riham M. Bokhtia, Mohammed A. AlAwadh, Israa A. Seliem, Hani Z. Asfour, and et al. 2020. "In Vitro Antimycobacterial Activity and Physicochemical Characterization of Diaryl Ether Triclosan Analogues as Potential InhA Reductase Inhibitors" Molecules 25, no. 14: 3125. https://doi.org/10.3390/molecules25143125

Article Metrics

Back to TopTop